证券代码：300109 证券简称：新开源 公告编号：2024-077 博爱新开源医疗科技集团股份有限公司 关于控股股东、实际控制人之一部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"本公司"） 于近日收到公司控股股东、实际控制人之一王东虎先生的通知，获悉王东虎先生 所持有的本公司部分股份办理了解除质押业务，具体事项如下： 一、控股股东、实际控制人之一股份解除质押情况 | | 是否为控股股 东及其一致行 | 本次解除质押 | 占其所持 | 占公司总 | | 解除日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | | 股份数量（股） | 股份比例 | 股本比例 | 起始日 | 期 | 质权人 | | | 动人 | | (%) | （%） | | | | | | | | | | 2023 年 | 2024 年 | 中国银河证券股 | | 王东虎 | 是 | 1,150,000 | 2.73 | 0.24 | 9 ...

Core Viewpoint - The China National Medical Products Administration (NMPA) has included the CAR-T-19 cell injection developed by Yongtai Biotech, a subsidiary of New Open Source, in its list of breakthrough therapies, targeting relapsed/refractory B-cell acute lymphoblastic leukemia in patients aged 25 and under [1] Group 1 - The CAR-T-19 cell injection is a chimeric antigen receptor T-cell therapy targeting CD19 [1] - The inclusion in the breakthrough therapy list signifies a potential acceleration in the development and approval process for this treatment [1] - The targeted patient population is specifically those aged 25 years and younger, indicating a focus on pediatric and young adult oncology [1]

证券代码：300109 证券简称：新开源 公告编号：2024-076 博爱新开源医疗科技集团股份有限公司 关于为晶能生物技术（上海）有限公司提供连带责任担保的 公 告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示: 被担保人名称：公司全资子公司晶能生物技术（上海）有限公司（以下简称 "晶能生物"） 本次担保总金额：总计不超过 500 万元 本次担保是否有反担保：无 公司对外担保不存在逾期担保情况 二、被担保方基本情况 | | | 2024 年 10 月 21 日，博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）召开了第五届董事会第十四次会议，审议并通过《关于为晶能生物技术（上 海）有限公司提供连带责任担保的议案》，具体情况如下： 一、担保情况概述 为满足晶能生物日常经营和业务发展的需求，晶能生物拟向江苏银行股份有 限公司上海长宁支行申请不超过 500 万元（含）银行融资额度，以上申请额度用 于补充流动资金业务，贷款期限为一年。公司为其提供不超过上述银行融资额度 的连带责任担保。 具体条款以其与银行签订的《流动资金借款合同》、《保证合同》为准 ...

证券代码：300109 证券简称：新开源 公告编号：2024-075 博爱新开源医疗科技集团股份有限公司 第五届监事会第十次会议决议公告 经与会监事审议，表决通过以下议案： 二、监事会会议审议情况 （一）审议并通过《关于 2024 年第三季度报告的议案》 经审核，监事会认为公司《2024 年第三季度报告》编制和审议的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 《2024 年第三季度报告》详见公司同日在中国证监会指定创业板信息披露 网站巨潮资讯网发布的公告。 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"新开源"） 第五届监事会第十次会议于 2024 年 10 月 21 日下午在公司三楼会议室以现场加 通讯的表决方式召开，本次会议通知已于 2024 年 10 月 18 日以电子邮件形式发 出。 本次会议由公司监事会主席阎重朝先生主 ...

证券代码：300109 证券简称：新开源 公告编号：2024-072 博爱新开源医疗科技集团股份有限公司 2024 年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）于 2024 年 10 月 21 日召开第五届董事会第十四次会议，审议并通过《关于 2024 年第三季度报 告的议案》。 为使投资者全面了解公司第三季度的财务状况及具体经营情况，公司于 2024 年 10 月 22 日在中国证监会指定的创业板信息披露网站巨潮资讯网上披露 《2024 年第三季度报告全文》，敬请广大投资者注意查阅！ 特此公告 博爱新开源医疗科技集团股份有限公司 董事会 2024 年 10 月 22 日 ...

证券代码：300109 证券简称：新开源 公告编号：2024-074 博爱新开源医疗科技集团股份有限公司 第五届董事会第十四次会议决议公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： （一）审议并通过《关于 2024 年第三季度报告的议案》 经与会董事认真核查，一致认为：公司编制《2024 年第三季度报告》的程序 符合法律、法规和中国证监会的规定，报告内容真实、准确、完整的反映了公司 的财务状况和经营成果，不存在虚假记载、误导性陈述和重大遗漏。 公司董事会审计委员会已审议通过本议案。 公司监事会对本议案发表了审核意见。 一、董事会会议召开情况 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"新开源"） 第五届董事会第十四次会议于 2024 年 10 月 21 日上午在公司三楼会议室以现场 加通讯的表决方式召开，本次会议通知已于 2024 年 10 月 18 日以电子邮件形式 发出。 本次会议由公司董事长张军政先生主持，应出席董事 9 名，实际出席董事 9 名，公司部分监事和高级管理人员列 ...

证券代码：300109 证券简称：新开源 公告编号：2024-071 博爱新开源医疗科技集团股份有限公司 关于控股股东、实际控制人之一部分股权质押的公告 公司控股股东、实际控制人之一王东虎先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、股东股份质押的基本情况 | | 是否为控 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押 | 占其所 | 占公司 | 是否为 | 是否为 | 质押起 | 质押到 | | 质押用 | | 名称 | 第一大股 | 数量（股） | 持股份 | 总股本 | 限售股 | 补充质 | 始日 | 期日 | 质权人 | 途 | | | 东及其一 | | 比例（%） | 比例（%） | | 押 | | | | | | | 致行动人 | | | | | | | | | | | | | | | | | | | 质押到 | 上海 ...

证券代码：300109 证券简称：新开源 公告编号：2024-070 博爱新开源医疗科技集团股份有限公司 关于部分高级管理人员股份减持计划的预披露公告 高级管理人员邹晓文先生、李社刚先生保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 本公司于近日收到高级管理人员邹晓文先生、李社刚先生《股份减持计划的 告知函》，现将相关情况公告如下： 一、股东的基本情况 1.股东名称：邹晓文、李社刚 | 股东名称 | 股东职务 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 邹晓文 | 副总经理 | 667,904 | 0.14 | | 李社刚 | 副总经理 | 330,000 | 0.07 | | 合计 | | 997,904 | 0.21 | 2.截至本公告披露日股东持股情况： | | 减持原 | 减持 | 股份来 | 计划减持股 | 占公司总 | | | | | --- | --- | --- | --- | --- | --- | --- | --- ...

Investment Rating - Maintains an "Overweight" rating with a target price adjustment to 15.29 yuan [1][4] Core Views - Q2 performance declined sequentially, in line with expectations, with PVP sales showing stable growth over the past 8 years, solidifying its leading position [1] - Revenue for 24H1 was 735 million yuan, down 5.68% YoY, with net profit attributable to shareholders at 213 million yuan, down 18.79% YoY [4] - Q2 revenue was 340 million yuan, down 18.24% YoY and 13.83% QoQ, with net profit attributable to shareholders at 92 million yuan, down 35.64% YoY and 24.59% QoQ [4] - Gross margin and net margin for Q2 were 57.06% and 27.24%, respectively, with gross margin increasing by 3.57 pct QoQ and net margin decreasing by 3.39 pct QoQ [4] - The company continues to optimize its product structure, increasing the proportion of high-end products, and maintains a leading position in the global PVP industry [4] - New projects, including a 10,000-ton pharmaceutical-grade PVP and 2,000-ton PVP-I project, are progressing, with PVP-I revenue up 69.96% YoY in 24H1 [4] Financial Summary - Revenue for 2022A was 1,486 million yuan, increasing to 1,583 million yuan in 2023A, and is projected to reach 2,996 million yuan by 2026E [3] - Net profit attributable to shareholders was 291 million yuan in 2022A, increasing to 493 million yuan in 2023A, and is projected to reach 686 million yuan by 2026E [3] - EPS for 2022A was 0.60 yuan, increasing to 1.02 yuan in 2023A, and is projected to reach 1.42 yuan by 2026E [3] - ROE was 9.3% in 2022A, increasing to 13.9% in 2023A, and is projected to reach 13.5% by 2026E [3] - PE ratio was 18.33 in 2022A, decreasing to 10.83 in 2023A, and is projected to reach 7.79 by 2026E [3] Industry and Market Position - The company holds a leading position in the global PVP industry, ranking first in China and third globally [4] - PVP is widely used in pharmaceuticals, industrial applications, food, and daily chemicals, with the company's competitive advantage expected to strengthen [4] Growth and Expansion - The company is expanding its capacity and upgrading its product matrix, with new projects expected to drive future growth [4] - PVP-I revenue increased by 69.96% YoY in 24H1, and the company's R&D capabilities are highlighted by the growth of its Oricid series products [4] Valuation and Target Price - The target price is adjusted to 15.29 yuan based on a 2024 PE of 16X, reflecting the company's growth prospects and industry position [4] - The current price is 10.95 yuan, with a 52-week price range of 10.57-23.70 yuan [6]

Revenue and Growth - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 15% increase compared to the same period last year[3]. - The company has provided a revenue guidance of RMB 1.2 billion for the full year 2024, which reflects a projected growth of 10%[3]. - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2024, representing a 25% year-over-year growth[8]. - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20%[8]. - The company reported a revenue of 2726.38 million for the first half of 2024, reflecting a significant growth compared to the previous period[33]. - The company has set a future outlook aiming for a revenue growth of 15% year-over-year for the next fiscal year[33]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2024, representing a 20% year-over-year growth[43]. - The company has provided guidance for the second half of 2024, expecting revenue to grow by an additional 25% compared to the first half[44]. - The company reported a total revenue of RMB 5 billion for the first half of 2024, representing a 15% increase year-over-year[118]. User Growth and Engagement - User data indicates a growth in active users by 20%, reaching a total of 1.2 million users by June 30, 2024[3]. - User data indicates a growth in active users, reaching 1.2 million, which is a 15% increase compared to the previous year[8]. - User data indicates a rise in active users by 25%, reaching 1.5 million users in the same period[38]. - User data indicates a 30% increase in active users of the company's medical technology platforms, reaching 500,000 users by June 30, 2024[49]. - User data showed an increase in active users to 2 million, up 20% from the previous year[119]. Product Development and Innovation - New product launches in the first half of 2024 included three innovative medical devices, contributing to 30% of total sales[3]. - New product development includes advancements in molecular diagnostics, with a focus on DNA sequencing technology expected to launch by Q4 2024[7]. - New product launches are expected to drive additional revenue, with at least three new products scheduled for release in Q3 2024[33]. - New product development includes the introduction of five innovative dental care products, expected to contribute an additional 10 million RMB in revenue[38]. - New product development includes the launch of a non-medical UV lamp, which is expected to contribute an additional 5 million CNY in revenue by the end of the year[40]. - New product developments include the launch of an automated gene amplification device, which is expected to enhance operational efficiency by 40%[49]. - New product launches include a universal sequencing reagent kit and a methylation detection sample preparation kit, both expected to enhance market competitiveness[63]. Market Expansion - The company is expanding its market presence in Southeast Asia, with plans to enter two new countries by the end of 2024[3]. - The company is expanding its market presence, targeting new regions in Southeast Asia, aiming for a 30% market share by the end of 2025[8]. - Market expansion plans include entering two new international markets by the end of 2024, targeting a 20% increase in market share[33]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[38]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[43]. - The company is expanding its market presence by entering new regions, targeting a 15% increase in market share by the end of 2024[64]. Research and Development - Research and development expenses increased by 25%, totaling RMB 100 million, focusing on advanced medical technologies[3]. - The company has invested 50 million RMB in research and development for new healthcare technologies[8]. - The company has invested in several biotech firms to strengthen its capabilities in precision diagnostics and treatment, expanding its core business areas[22]. - The company is actively investing in research and development for innovative products, particularly in the fields of dental and personal care[36]. - Research and development expenditures have increased by 10% to 150 million CNY, focusing on innovative diagnostic technologies[49]. - Research and development expenses rose significantly to CNY 35,947,173.39, an increase of 51.4% compared to CNY 23,725,240.84 in the previous year[165]. Financial Performance - The company's operating revenue for the reporting period was ¥734,804,462.96, a decrease of 5.68% compared to the same period last year[13]. - Net profit attributable to shareholders was ¥212,929,814.26, down 18.79% year-on-year[13]. - The net profit after deducting non-recurring gains and losses was ¥218,300,190.74, reflecting a decrease of 15.36% compared to the previous year[13]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[8]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2024, representing a 25% year-over-year growth[51]. - The company reported a significant increase in tax expenses, which rose to CNY 39,270,942.52 from CNY 73,704,647.42 year-over-year[166]. Strategic Acquisitions - The company has completed the acquisition of a local competitor, which is expected to enhance market share by 5%[3]. - A strategic acquisition of a biotechnology firm was completed, enhancing the company's capabilities in precision medicine[8]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with potential targets identified[33]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product portfolio and increase operational efficiency, expected to close by Q4 2024[38]. - The company has initiated a strategic acquisition of a smaller biotech firm, which is anticipated to contribute an additional 200 million CNY in annual revenue starting in 2025[49]. Marketing Strategies - The company plans to implement a new digital marketing strategy aimed at increasing online sales by 40% in the next six months[3]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 10 million RMB[8]. - A new marketing strategy has been implemented, focusing on digital channels, which is projected to increase customer engagement by 30%[33]. - The company plans to enhance its online sales platform, aiming for a 50% increase in e-commerce sales by the end of 2024[38]. - A new marketing strategy focusing on digital channels is expected to increase customer engagement and drive sales growth by 10% in the next quarter[51]. Compliance and Quality Management - The company is committed to maintaining compliance with international standards, including GMP and ISO certifications, to ensure product quality[8]. - The company emphasizes high-quality management and has obtained certifications such as the Drug Production License and GMP Certificate to ensure product quality[30]. - The company has received multiple certifications for its quality management systems, ensuring compliance with international standards[63]. Environmental and Social Responsibility - The company reported an investment of CNY 234,700 in environmental governance and protection from January 1 to June 30, 2024, along with CNY 19,700 paid in environmental protection taxes[108]. - The company has implemented measures for noise reduction through foundational vibration reduction and sound insulation[108]. - The company is committed to sustainability, with initiatives aimed at reducing operational carbon emissions by 10% in the next year[63].